Metastatic triple-negative Breast Cancer (mTNBC) - Second-line Therapy mTNBC: Sacituzumab Govitecan with high Effectiveness even in HER2-low

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：343 / 343
页数：1
相关论文
共 50 条
  • [1] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [2] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [3] Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
    Kalinsky, K.
    Spring, L.
    Yam, C.
    Ntalla, I.
    Stwalley, B.
    Sjekloca, N.
    Lai, C.
    Kaushiva, A.
    Taylor, A. J.
    Nanda, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S345 - S346
  • [4] COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN
    Yamaguchi, M.
    Maeda, T.
    Morimoto, K.
    Chen, W.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [5] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
  • [6] Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results
    Seneviratne, Lasika C.
    Harnden, Kathleen Kiernan
    Blau, Sibel
    Danso, Michael A.
    Berz, David
    Guaqueta, Delia Constanza
    Schwerkoske, John F.
    O'Shaughnessy, Joyce
    Patt, Debra A.
    Bardia, Aditya
    McCann, Kelly Elizabeth
    Beelen, Andrew Paul
    Zhang, Jingshan
    Yi, John S.
    Hurvitz, Sara A.
    Mardones, Mabel Alejandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] HEALTH UTILITIES ASSOCIATED WITH SACITUZUMAB GOVITECAN (SG) FOR TREATING UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
    Benedict, A.
    Rakonczai, P.
    Lovato, E.
    Proskorovsky, I
    Xiao, Y.
    Hodgson, M.
    McConkey, D.
    Gharaibeh, M.
    VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
  • [8] Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Loibl, S.
    Loirat, D.
    Tolaney, S. M.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Bardia, A.
    Hurvitz, S. A.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Gharaibeh, M.
    Moore, L.
    Shi, L.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S472 - S473
  • [9] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Singh, Indrajeet
    Sathe, Abhishek G.
    Singh, Pratap
    Diderichsen, Paul M.
    Fauchet, Floris
    Maringwa, John
    Pierrillas, Philippe
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
12345